The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Researchers identify gut bacteria as key to ovarian cancer immunotherapy resistance

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

University of Virginia Cancer Center researchers explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP). 
By Lee Greenberger
Clinical Roundup

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account